Drug Trial Radar · NCT04638660
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
144
Actual
Start
Dec 30, 2020
Primary completion
May 19, 2022
Study completion May 19, 2022
Sponsor
- Lead sponsor
- Opus Genetics, IncIndustry
- Sponsor type
- Industry
- First posted
- Nov 20, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of this study are: * To evaluate the efficacy of Nyxol to improve mesopic low contrast visual acuity (mLCVA) in subjects with Dim Light Vision Disturbances (DLD) * To evaluate efficacy of Nyxol to improve visual performance * To evaluate the safety of Nyxol
Conditions
- Dim Light Vision Disturbances
Interventions
Phentolamine Ophthalmic Solution 0.75%Drug
0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
Phentolamine Ophthalmic Solution Vehicle (Placebo)Drug
Topical sterile ophthalmic solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent of Subjects With 3 Lines mLCVA Improvement in Study EyeTime frame: 8 days
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Clinical Site 6
Newport Beach, California
Clinical Site 1
Petaluma, California
Clinical Site 3
Jacksonville, Florida
Clinical Site 18
Jacksonville, Florida
Clinical Site 13
Pittsburg, Kansas
Clinical Site 20
Edgewood, Kentucky
Clinical Site 14
Louisville, Kentucky
Clinical Site 10
Palisades Park, New Jersey
Clinical Site 8
Pennington, New Jersey
Clinical Site 4
Elizabeth City, North Carolina
Clinical Site 22
High Point, North Carolina
Clinical Site 9
High Point, North Carolina
Clinical Site 2
Fargo, North Dakota
Clinical Test 15
Warwick, Rhode Island
Clinical Site 11
Memphis, Tennessee
Clinical Site 5
San Antonio, Texas
Clinical Site 19
Ogden, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.